Overview of influenza vaccination policy in Beijing, China: Current status and future prospects

Zhang, Yi; Muscatello, David; Wang, Quanyi; Yang, Peng; Wu, Jiang; MacIntyre, C. Raina

doi:10.1057/s41271-017-0079-7

Cited by 27 publications

(30 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…School‐based influenza vaccination programs have therefore been recommended in some settings as an extension of existing influenza vaccination programs but remain rare globally . In Beijing, in 2009, a free influenza vaccination policy was launched in primary, secondary, and high schoolchildren who are 6‐18 years old . Temporary points of vaccination (POVs) are established at schools, and students with their parent's written consent are organized to receive the vaccination there.…”

Section: Introductionmentioning

confidence: 99%

“…3,4 In Beijing, in 2009, a free influenza vaccination policy was launched in primary, secondary, and high schoolchildren who are 6-18 years old. 5 Temporary points of vaccination (POVs) are established at schools, and students with their parent's written consent are organized to receive the vaccination there. Moreover, students are able to receive the free vaccination at community POVs located if the temporary school POVs are closed.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Influenza illness averted by influenza vaccination among school year children in Beijing, 2013‐2016

Zhang

Cao

Costantino

et al. 2018

Influenza Resp Viruses

Self Cite

View full text Add to dashboard Cite

BackgroundThe benefit of school‐based influenza vaccination policy has not been fully addressed in Beijing.ObjectivesTo evaluate the benefit of school‐based influenza vaccination policy launched in Beijing.MethodsUsing existing surveillance and immunization data, we developed a dynamic transmission model to assess the impact of influenza vaccination in school‐going children. The outcome was defined as the averted number of medically attended influenza illnesses and the prevented disease fraction to all children aged 5‐14 years for the 2013/14, 2014/15, and 2015/16 seasons.ResultsWe estimated that during the three consecutive influenza seasons, the averted number of medically attended influenza illnesses among children aged 5‐14 years was around 104 000 (95% CI: 101 000‐106 000), 23 000 (95% CI: 22 000‐23 000), and 21 000 (95% CI: 21 000‐22 000), respectively. Corresponding prevented fractions to all children aged 5‐14 years were 76.3%, 38.5%, and 43.9%.ConclusionsIn Beijing, school‐based vaccinations reduced a substantial number of medically attended influenza illnesses despite seasonal variation in the prevented fraction. This is strong supportive evidence for the continuation of school‐based vaccination programs to reduce the influenza burden in this age group.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Influenza illness averted by influenza vaccination among school year children in Beijing, 2013‐2016

Zhang

Cao

Costantino

et al. 2018

Influenza Resp Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

“…37 Based on data from the Beijing Municipal Center for Disease Control and Prevention, after the implementation of publicly funded vaccination, the influenza vaccination rate in elderly people was approximately 50% from 2011 to 2015, which was significantly higher than it had previously been. 39…”

Section: Current Status Of Influenza Vaccination In Elderly People mentioning

confidence: 99%

Recommendations for influenza and Streptococcus pneumoniae vaccination in elderly people in China

et al. 2020

View full text Add to dashboard Cite

Influenza and pneumonia can be prevented by vaccination, but they remain major causes of morbidity and mortality in age‐related diseases. In most areas of China, the rates of influenza and pneumococcal vaccination are relatively low and public awareness of vaccination remains insufficient. Thus, it is essential to recommend influenza and Streptococcus pneumoniae vaccination to elderly people in clinical practice. Based on recently published studies and related documents issued by several vaccination authorities, such as the World Health Organization, the National Health and Wellness Committee, the Chinese Center for Disease Control and Prevention, the US Centers for Disease Control and Prevention, and the US Advisory Committee on Immunization Practices, we propose official recommendations for influenza and S pneumoniae vaccination in elderly people in China.

show abstract

“…8 The low vaccine coverage is likely due to the exclusion of influenza vaccines from the national immunization program, meaning that individuals must pay for the vaccine voluntarily. 7,9 Consequently, new policies are being explored in China to improve vaccine accessibility among at-risk populations, such as free vaccination for older persons. 9 Since 2013, a split virion trivalent inactivated influenza vaccine (IIV3) has been produced by the Sanofi Pasteur facilities based at Shenzhen, China (Shz-IIV3) according to Chinese pharmacopeia requirements.…”

mentioning

confidence: 99%

“…7,9 Consequently, new policies are being explored in China to improve vaccine accessibility among at-risk populations, such as free vaccination for older persons. 9 Since 2013, a split virion trivalent inactivated influenza vaccine (IIV3) has been produced by the Sanofi Pasteur facilities based at Shenzhen, China (Shz-IIV3) according to Chinese pharmacopeia requirements. 10 Shz-IIV3 is well tolerated and highly immunogenic in Chinese individuals aged ≥ 6 months, 10 but its immunogenicity and safety compared to existing IIV3s in China have not been assessed.…”

mentioning

confidence: 99%

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study

Cui

Lavis

et al. 2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Seasonal influenza causes substantial morbidity and mortality in China, which largely results from limited vaccine accessibility and poor vaccination coverage. Since 2013, Sanofi Pasteur's facilities in Shenzhen, China have produced a trivalent inactivated influenza vaccine (Shz-IIV3) for each influenza season according to Chinese pharmacopeia requirements. However, the immunogenicity of Shz-IIV3 has not been compared to existing Chinese trivalent inactivated influenza vaccines (IIV3s). Here, we describe the results of a phase IV, observer-blind, randomized study to evaluate whether the immunogenicity of Shz-IIV3 was non-inferior to a comparator IIV3 (Hualan Biological Engineering Inc) also manufactured and licensed in China. Healthy adults aged 18−59 years were randomly assigned in a 1:1 ratio to receive a single 0.5-mL intramuscular injection of the 2017-2018 Northern Hemisphere formulation of Shz-IIV3 (n = 800) or the comparator IIV3 (n = 799). Between baseline and day 28 after vaccination, hemagglutination inhibition titers for the three vaccine strains increased by at least 4-fold and were of similar magnitude in Shz-IIV3 and comparator IIV3 recipients. The rate of seroconversion or significant increase in titers was 62% to 92% in Shz-IIV3 recipients, and 63% to 91% in comparator IIV3 recipients. Postvaccination hemagglutination inhibition titers and seroconversion rates for Shz-IIV3 were statistically non-inferior to the comparator IIV3 for all three influenza vaccine strains. Rates of solicited and unsolicited vaccine-related adverse events were similar between the two vaccine groups. These results demonstrated that Shz-IIV3 was as immunogenic and safe in adults as a comparator Chinese IIV3, and support the continued use of Shz-IIV3 in China.

show abstract

Overview of influenza vaccination policy in Beijing, China: Current status and future prospects

Cited by 27 publications

References 46 publications

Influenza illness averted by influenza vaccination among school year children in Beijing, 2013‐2016

Influenza illness averted by influenza vaccination among school year children in Beijing, 2013‐2016

Recommendations for influenza and Streptococcus pneumoniae vaccination in elderly people in China

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study

Contact Info

Product

Resources

About